DOCSLIB.ORG

Molecular Characterization of Ductal Carcinoma in Situ: Pilot Studies Neil Bipinchandra Desai Yale University

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Characterization of Ductal Carcinoma in Situ: Pilot Studies Neil Bipinchandra Desai Yale University Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2010 Molecular Characterization of Ductal Carcinoma In Situ: Pilot Studies Neil Bipinchandra Desai Yale University Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl Part of the Medicine and Health Sciences Commons Recommended Citation Desai, Neil Bipinchandra, "Molecular Characterization of Ductal Carcinoma In Situ: Pilot Studies" (2010). Yale Medicine Thesis Digital Library. 153. http://elischolar.library.yale.edu/ymtdl/153 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. Molecular Characterization of Progression in Ductal Carcinoma In Situ: Pilot Studies A Thesis Submitted to the Yale University School of Medicine in Partial Fulfillment of the Requirements of the Degree of Doctor of Medicine by Neil Desai 2010 ! "! Abstract MOLECULAR CHARACTERIZATION OF PROGRESSION IN DUCTAL CARCINOMA IN SITU: PILOT STUDIES Neil B. Desai,1 Arun Gopinath,1 Sebastian Szpakowski,1 Rajini Haraksingh,3 Veerle Bossuyt,1 Michael O. Krauthammer,1 David Tuck,1 Donald R. Lannin,2 and David F. Stern.1 1Department of Pathology, Yale University, School of Medicine, New Haven, CT. 2Department of Surgery, Yale University, School of Medicine. 3Department of Genetics, Stanford University, Palo Alto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cknowledgements This work was funded by a grant from the Susan G. Komen Foundation and the thesis candidate’s research fellowship from the Howard Hughes Medical Institute. It was performed with the mentorship and guidance of the candidate’s principal investigator David F. Stern, Ph.D and the members of his laboratory, including in no order: Maureen Gilmore-Hebert Ph.D, Alexandra Teixeira, Christina Zito Ph.D, Kathleen Wilson, Jerrica Breindel, Kathryn Tworkoski, Kerry Williams, and Rahul Dalal. Notable collaborators involved in the project were David Rimm M.D. and his laboratory including Arun Gopinath M.D. and Seema Agarwal Ph.D, Fatteneh Tavassoli M.D., Veerle Bossuyt M.D., Lyndsay Harris M.D. and her laboratory including Kyle Halligan and Kimberly Lezon-Geyda Ph.D., Donald Lannin M.D., Director of the Breast Cancer Center at Yale, Ruth Halaban Ph.D, Mario Sznol M.D., Michael Krauthammer M.D., Ph.D and his lab including Sebastian Szpakowski, James B. Hicks Ph.D and his laboratory at Cold Spring Harbor , and David Tuck M.D and his laboratory including Vince Schulz. Other collaborators were Michael Snyder Ph.D and his lab now at Stanford University including Rajini Haraksingh. This work is also thankful for the support of the Office of Student Research at Yale University School of Medicine, including Dr. John Forrest, Donna Carranzo, and Mae Geter. Finally, this thesis candidate’s work on this study and otherwise is as always indebted to those relatives, especially parents, and friends who have supported and enabled his goals. ! V! Table of Contents !"#$%&'(#)%"****************************************************************************************************************************** +! ,%"#-.#'/0123-$3)-4************************************************************************************************************************+! 5)%0%671%819'(#/01,/$()"%:/1!"1;)#'********************************************************************************************<! #/01!/(,37(8!W737-;(73!0+:'3*:7!#*37'37!,+!'!L,(7%$(')!X7:7( ================================================Y! #/01!*3!L,(7%$(')(8!#*3&*+%&!>),-!X733!Z6:'+%76!O)7%$)3,)3=====================================================[! =%&-0>1%81?$%6$->>)%"1%819,!;1#%1!"3/>)3-19)>-/>- ************************************************************ @A! L*%),7+:*),+-7+&!H47,)8======================================================================================================================="D! Z!/,--,+!1&7-!/7((!O),57+*&,)!>,)!#/01!'+6!0</\======================================================================""! ,0)")(/01B-/#'$->1/"&1C$-/#:-"#1!>>'-> ********************************************************************************* @D! #*'5+,3*3=========================================================================================================================================================="U! H)7'&-7+& ========================================================================================================================================================"V! W7%$))7+%7 ======================================================================================================================================================"A! =%0-('0/$1EFF$%/(G->1#%1?$%6"%>#)(1?$-&)(#)%"***************************************************************** @H! O),397%&*:7!L7&4,6,(,58!X*-*&'&*,+3!'+6!Z6:'+%73==================================================================="]! W7&),397%&*:7!L7&4,6,(,58!X*-*&'&*,+3!'+6!Z6:'+%73 =============================================================="[! L'33!L$&'&*,+!1%)77+*+5==========================================================================================================================T"! ;'::/$71%81I/#)%"/0- ****************************************************************************************************************** DD! 2JK-(#)3-> ********************************************************************************************************************************DL! =-#G%&>************************************************************************************************************************************D<! 1&'&7-7+&!,>!0+:,(:7-7+&!*+!PK97)*-7+&!'+6!#73*5+==================================================================TA! /'37!17(7%&*,+=================================================================================================================================================TA! Z)%4*:'(!197%*-7+!O)79')'&*,+==============================================================================================================TY! NNOP!^$%(7*%!Z%*6!PK&)'%&*,+==================================================================================================================T]! WHMO/W ==============================================================================================================================================================T[! #Z1X!_(*5,+$%(7,&*67!L*%),'))'8=========================================================================================================T[! NNOP!#^Z!17Q$7+%*+5================================================================================================================================UD! PK,+!/'9&$)7!E*54MH4),$549$&!17Q$7+%*+5====================================================================================U"! I->'0#> **************************************************************************************************************************************M<! 23-$3)-4 ******************************************************************************************************************************************* M<! =%0-('0/$1/"/07>)>1%81/$(G)3/01#)>>'->************************************************************************************* M<! H*33$7!37(7%&*,+C!X/LC!'+6!+$%(7*%!'%*6!7K&)'%&*,+========================================================================UA! W^Z!PK9)733*,+!Z+'(83*3 ==========================================================================================================================U]! #^Z!-$&'&*,+!)7M37Q$7+%*+5!;8!O/W!9*(,& =======================================================================================VT! ;-0-(#)3-1G)6GN#G$%'6GF'#1>-O'-"()"6 *********************************************************************************** LM! #73*5+================================================================================================================================================================VU!
Load more

Recommended publications
  • A Novel Breast Cancer ^ Associated BRIP1 (FANCJ/BACH1) Germ- Line Mutation Impairs Protein Stability and Function
    Cancer Prevention and Susceptibility A Novel Breast Cancer ^ Associated BRIP1 (FANCJ/BACH1)Germ- line Mutation Impairs Protein Stability and Function Arcangela De Nicolo,1MariellaTancredi,4 Grazia Lombardi,4 Cristina Chantal Flemma,4 Serena Barbuti,4 Claudio Di Cristofano,4 Bijan Sobhian,1Generoso Bevilacqua,4 Ronny Drapkin,2,3 andMariaAdelaideCaligo4 Abstract Purpose: BRCA1-interacting protein 1 (BRIP1; FANCJ/BACH1), which encodes a DNA helicase that interacts with BRCA1, has been suggested to be a low-penetrance breast cancer predispos- ing gene.We aimed to assess whether BRIP1 mutations contribute to breast cancer susceptibility in our population and, if so, to investigate the effect of such mutation(s) on BRIP1function. Experimental Design: A series of49 breast/ovarian cancer families, devoid ofa BRCA1/ BRCA2 mutation, were screened for BRIP1 mutations. Functional analyses, including coimmuno- precipitation and stability assays, were employed to further characterize a previously unreported variant. Results: Five sequence alterations were identified, of which four had been already described. Herein, we report a novel BRIP1 germ-line mutation identified in a woman with early-onset breast cancer. The mutation consists ofa 4-nucleotide deletion (c.2992-2995delAAGA) in BRIP1 exon 20 that causes a shift in the reading frame, disrupts the BRCA1-binding domain of BRIP1, and creates a premature stop codon. Functional analysis ofthe recombinant mutant protein in transfected cells showed that the truncation interferes with the stability of the protein and with its ability to interact with BRCA1. Loss ofthe wild-type BRIP1 allele with retention ofthe mutated one was observed in the patient’s breast tumor tissue. Conclusions: These results, by showing that the newly identified BRIP1 c.2992-2995delAAGA mutation is associated with instability and functional impairment of the encoded protein, provide further evidence of a breast cancer ^ related role for BRIP1.
    [Show full text]
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Analysis of and Fanconi Anemia Genes in -Negative Spanish Breast Cancer Families María J
    Analysis of and Fanconi Anemia genes in -negative Spanish breast cancer families María J. García, Victoria Fernández, Ana Osorio, Alicia Barroso, Gemma Llort, Conxi Lázaro, Ignacio Blanco, Trinidad Caldés, Miguel Hoya, Teresa Ramón y Cajal, et al. To cite this version: María J. García, Victoria Fernández, Ana Osorio, Alicia Barroso, Gemma Llort, et al.. Analysis of and Fanconi Anemia genes in -negative Spanish breast cancer families. Breast Cancer Research and Treatment, Springer Verlag, 2008, 113 (3), pp.545-551. 10.1007/s10549-008-9945-0. hal-00478320 HAL Id: hal-00478320 https://hal.archives-ouvertes.fr/hal-00478320 Submitted on 30 Apr 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Breast Cancer Res Treat (2009) 113:545–551 DOI 10.1007/s10549-008-9945-0 EPIDEMIOLOGY Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families Marı´a J. Garcı´a Æ Victoria Ferna´ndez Æ Ana Osorio Æ Alicia Barroso Æ Gemma LLort Æ Conxi La´zaro Æ Ignacio Blanco Æ Trinidad Calde´s Æ Miguel de la Hoya Æ Teresa Ramo´n y Cajal Æ Carmen Alonso Æ Marı´a-Isabel Tejada Æ Carlos San Roma´n Æ Luis Robles-Dı´az Æ Miguel Urioste Æ Javier Benı´tez Received: 12 February 2008 / Accepted: 12 February 2008 / Published online: 27 February 2008 Ó Springer Science+Business Media, LLC.
    [Show full text]
  • Epigenetic Silencing of TGFBI Confers Resistance to Trastuzumab in Human Breast Cancer
    Palomeras et al. Breast Cancer Research (2019) 21:79 https://doi.org/10.1186/s13058-019-1160-x RESEARCH ARTICLE Open Access Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer Sònia Palomeras1†, Ángel Diaz-Lagares2,3†, Gemma Viñas1,4,5, Fernando Setien2, Humberto J. Ferreira2, Glòria Oliveras1,6, Ana B. Crujeiras7,8, Alejandro Hernández4, David H. Lum9, Alana L. Welm9, Manel Esteller2,10,11,12,13* and Teresa Puig1* Abstract Background: Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. The aim of this study was to identify novel epigenetic biomarkers associated to trastuzumab resistance in HER2+ BC patients. Methods: We performed a genome-wide DNA methylation (450K array) and a transcriptomic analysis (RNA-Seq) comparing trastuzumab-sensitive (SK) and trastuzumab-resistant (SKTR) HER2+ human breast cancer cell models. The methylation and expression levels of candidate genes were validated by bisulfite pyrosequencing and qRT-PCR, respectively. Functional assays were conducted in the SK and SKTR models by gene silencing and overexpression. Methylation analysis in 24 HER2+ human BC samples with complete response or non-response to trastuzumab- based treatment was conducted by bisulfite pyrosequencing. Results: Epigenomic and transcriptomic analysis revealed the consistent hypermethylation and downregulation of TGFBI, CXCL2, and SLC38A1 genes in association with trastuzumab resistance. The DNA methylation and expression levels of these genes were validated in both sensitive and resistant models analyzed. Of the genes, TGFBI presented the highest hypermethylation-associated silencing both at the transcriptional and protein level.
    [Show full text]
  • The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice
    G C A T T A C G G C A T genes Review The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice Luigia Stefania Stucci 1,* , Valeria Internò 1 , Marco Tucci 1,2 , Martina Perrone 1, Francesco Mannavola 1 , Raffaele Palmirotta 3 and Camillo Porta 1 1 Division of Medical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari ‘Aldo Moro’, A.O.U. Consorziale Policlinico di Bari, 70121 Bari, Italy; [email protected] (V.I.); [email protected] (M.T.); [email protected] (M.P.); [email protected] (F.M.); [email protected] (C.P.) 2 National Cancer Research Center, Tumori Institute IRCCS Giovanni Paolo II, 70121 Bari, Italy 3 Interdisciplinary Department of Medicine, Section of Sciences and Technologies of Laboratory Medicine, University of Bari, 70121 Bari, Italy; [email protected] * Correspondence: [email protected] Abstract: Molecular alterations of the Ataxia-telangiectasia (AT) gene are frequently detected in breast cancer (BC), with an incidence ranging up to 40%. The mutated form, the Ataxia-telangiectasia mutated (ATM) gene, is involved in cell cycle control, apoptosis, oxidative stress, and telomere maintenance, and its role as a risk factor for cancer development is well established. Recent studies have confirmed that some variants of ATM are associated with an increased risk of BC development and a worse prognosis. Thus, many patients harboring ATM mutations develop intermediate- and high-grade disease, and there is a higher rate of lymph node metastatic involvement. The evidence concerning a correlation of ATM gene mutations and the efficacy of therapeutic strategies in BC management are controversial.
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Targeting PH Domain Proteins for Cancer Therapy
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
    [Show full text]
  • Familial Cortical Myoclonus Caused by Mutation in NOL3 by Jonathan Foster Rnsseil DISSERTATION Submitted in Partial Satisfaction
    Familial Cortical Myoclonus Caused by Mutation in NOL3 by Jonathan Foster Rnsseil DISSERTATION Submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Biomedical Sciences in the Copyright 2013 by Jonathan Foster Russell ii I dedicate this dissertation to Mom and Dad, for their adamantine love and support iii No man has earned the right to intellectual ambition until he has learned to lay his course by a star which he has never seen—to dig by the divining rod for springs which he may never reach. In saying this, I point to that which will make your study heroic. For I say to you in all sadness of conviction, that to think great thoughts you must be heroes as well as idealists. Only when you have worked alone – when you have felt around you a black gulf of solitude more isolating than that which surrounds the dying man, and in hope and in despair have trusted to your own unshaken will – then only will you have achieved. Thus only can you gain the secret isolated joy of the thinker, who knows that, a hundred years after he is dead and forgotten, men who never heard of him will be moving to the measure of his thought—the subtile rapture of a postponed power, which the world knows not because it has no external trappings, but which to his prophetic vision is more real than that which commands an army. -Oliver Wendell Holmes, Jr. iv ACKNOWLEDGMENTS I am humbled by the efforts of many, many others who were essential for this work.
    [Show full text]
  • Rare Copy Number Variants Disrupt Genes Regulating Vascular Smooth Muscle Cell Adhesion and Contractility in Sporadic Thoracic Aortic Aneurysms and Dissections
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ARTICLE Rare Copy Number Variants Disrupt Genes Regulating Vascular Smooth Muscle Cell Adhesion and Contractility in Sporadic Thoracic Aortic Aneurysms and Dissections Siddharth K. Prakash,1 Scott A. LeMaire,2,3 Dong-Chuan Guo,4 Ludivine Russell,2 Ellen S. Regalado,4 Hossein Golabbakhsh,4 Ralph J. Johnson,4 Hazim J. Safi,5 Anthony L. Estrera,5 Joseph S. Coselli,2,3 Molly S. Bray,1 Suzanne M. Leal,1 Dianna M. Milewicz,4 and John W. Belmont1,* Thoracic aortic aneurysms and dissections (TAAD) cause significant morbidity and mortality, but the genetic origins of TAAD remain largely unknown. In a genome-wide analysis of 418 sporadic TAAD cases, we identified 47 copy number variant (CNV) regions that were enriched in or unique to TAAD patients compared to population controls. Gene ontology, expression profiling, and network anal- ysis showed that genes within TAAD CNVs regulate smooth muscle cell adhesion or contractility and interact with the smooth muscle- specific isoforms of a-actin and b-myosin, which are known to cause familial TAAD when altered. Enrichment of these gene functions in rare CNVs was replicated in independent cohorts with sporadic TAAD (STAAD, n ¼ 387) and inherited TAAD (FTAAD, n ¼ 88). The over- all prevalence of rare CNVs (23%) was significantly increased in FTAAD compared with STAAD patients (Fisher’s exact test, p ¼ 0.03). Our findings suggest that rare CNVs disrupting smooth muscle adhesion or contraction contribute to both sporadic and familial disease.
    [Show full text]